1. Home
  2. ANIX vs FORA Comparison

ANIX vs FORA Comparison

Compare ANIX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.48

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Logo Forian Inc.

FORA

Forian Inc.

HOLD

Current Price

$2.16

Market Cap

67.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
FORA
Founded
1982
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
88.8M
67.3M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ANIX
FORA
Price
$2.48
$2.16
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
103.9K
86.3K
Earning Date
05-27-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
25.00
EPS
N/A
N/A
Revenue
$210,000.00
$30,256,919.00
Revenue This Year
N/A
$8.44
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.13
52 Week Low
$2.32
$1.64
52 Week High
$5.46
$2.71

Technical Indicators

Market Signals
Indicator
ANIX
FORA
Relative Strength Index (RSI) 42.21 64.06
Support Level $2.44 $2.05
Resistance Level $3.12 $2.20
Average True Range (ATR) 0.15 0.01
MACD -0.01 -0.00
Stochastic Oscillator 39.58 66.67

Price Performance

Historical Comparison
ANIX
FORA

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

Share on Social Networks: